BMS Expands Oncology Portfolio with Eisai’s MORAb-202
By Neha Madhwani
Pharma Deals Review: Vol 2021 Issue 7 (Table of Contents)
Published: 28 Jul-2021
DOI: 10.3833/pdr.v2021.i7.2630 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bristol Myers Squibb (BMS) has agreed to pay US$650 M upfront to access Eisai’s anti-folate receptor alpha (FRalpha) antibody, MORAb-202, which is currently in a Phase I clinical study in Japan and Phase I/II trials in the US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS